Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Engineered probiotics for the control of antibiotic-resistant and difficult-to-treat pathogens.

Created on 04 Nov 2026

Authors

Seung-Gyun Woo

Published in

Folia microbiologica. Nov 03, 2026. Epub Nov 03, 2026.

Abstract

The increasing prevalence of antibiotic-resistant pathogens and recurrent, biofilm-associated, toxin-mediated, or dysbiosis-related infections has created an urgent need for strategies that complement conventional antibiotics. Broad-spectrum therapy can disrupt commensal microbiota, weaken colonization resistance, and promote opportunistic or recurrent infection. Engineered probiotics offer microbiology-based interventions that can inhibit pathogen growth, disrupt biofilms, attenuate virulence, neutralize toxins, and restore protective microbiota functions. Engineered probiotic and commensal microorganisms can also respond to pathogen- or infection-associated signals, improving therapeutic localization and specificity. This review summarizes strategies for controlling antibiotic-resistant and difficult-to-treat pathogens, including pathogen-responsive antimicrobial production, bacteriocin-, pyocin-, lysin-, and antimicrobial peptide-mediated inhibition, enzymatic biofilm degradation, anti-virulence and toxin-neutralization approaches, restoration of microbiota-mediated colonization resistance, and targeted genetic approaches for pathogen elimination or antibiotic resensitization. Representative systems against Pseudomonas aeruginosa, Clostridioides difficile, Staphylococcus aureus, Listeria monocytogenes, Streptococcus pyogenes, and resistant Enterobacteriaceae are discussed. Major translational challenges include chassis selection, genetic stability, horizontal gene transfer, biocontainment, delivery, manufacturing, regulation, and host-microbiota variability. Engineered probiotics may therefore provide selective, localized, and microbiota-preserving complements to conventional therapy.

PMID:
42975792
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement